Edinburgh Biosciences secures £2.3 million for cataract treatment tech
Summary
The funding will support the launch of Revisyon, as it approaches the final stages of market readiness and initiates commercial activities.This latest round of funding follows \xa32m raised from Innofield Biotechnology, a wholly owned subsidiary of Boye Biotech, in 2023, as part of a licensing and equity deal.Edinburgh Biosciences has recently completed clinical trials on Revisyon, which will allow cataract treatment to move from the operating theatre to the high street.The new treatment, which can be delivered by an optometrist, should shorten the care pathway for the millions of people awaiting cataract surgery each year.Edinburgh Biosciences expects to receive the UKCA mark by the end of this year and will then bring Revisyon to market.Chief executive Graham Bell said: This technology has the capability to transform our approach to cataract treatment.We have backers who support our vision and are equally excited about the global possibilities presented by Revisyon.Bell is presenting initial clinical trial findings at the LSX World Congress in London this week. Trial results show that Revisyon improves visual acuity, with full clinical trial data expected to be published over the summer.The new treatment, initially conceived by Edinburgh Biosciences founder, professor Desmond Smith OBE, is based on his body of work into light-based technologies. He discovered that lower power LED light had the ability to treat cataracts and started development of the new treatment.After extensive research, the company discovered that light of a specific wavelength had the ability to reverse the build up of aggregates which causes the lens to become cloudy.Smith died in 2023 before seeing his invention come to fruition, but his family and colleagues have continued his pioneering work, which has seen the creation of a prototype and final model of the testing equipment, development of software, completion of clinical trials and preparation for regulatory submission, as well as research among opticians and optometrists.The professors daughter, Dr Nicky Abraham, has maintained a minority shareholding in the business. Speaking about her fathers legacy, she said; The family is delighted that dads legacy will live on through Revisyon and the continued work of Edinburgh Biosciences.He was absolutely passionate about his work around fluorescence and light-based technologies and the ability to use them to diagnose and treat cataracts.Its amazing to see his final project come to life.Dont miss the latest headlines with our twice-daily newsletter - sign up here for free.
Funding
Review available funding amount, funding date, investors, and linked company information related to Edinburgh Biosciences secures £2.3 million for cataract treatment tech in the interactive ISVWorld profile.